Mina Lakshman

Dr Mina Lakshman is a healthcare AI commercialization leader, scientist, and venture advisor with over 15 years of experience translating clinical innovation into scalable market impact. Her career spans laboratory medicine, translational research in Oncology, life sciences commercialization, digital pathology, artificial intelligence, and venture development, positioning her at the intersection of science, technology, and healthcare innovation.

Trained as a PhD scientist in Laboratory Medicine and Pathobiology, she completed postdoctoral research in Experimental Therapeutics and led preclinical drug development and translational research in oncology and pathology. Deliberate was her transition to commercial leadership after a fellowship on commercialization in affiliation with Rotman School of Management

Motivated by the observation that many promising healthcare innovations fail to reach patients due to gaps between science, regulation, and market adoption, she built her career around bridging those disciplines  Throughout her career, she has specialized in building the commercial architecture that transforms emerging healthcare technologies into sustainable businesses. At Standard BioTools (formerly Fluidigm), she scaled a global imaging business unit to double digit growth through multiple product launches, including the industry’s first 18-plex immuno-oncology panel. These efforts generated more than 50 peer-reviewed publications, supported multiple clinical trials, and contributed to a landmark publication in Nature within three years of launch.

As a commercial leader in healthcare AI, she has led strategic partnerships with Visiopharm, and Indica Labs while at Standard Bio Tools and with Microsoft (Nuance), Leica Biosystems, while at Paige AI, supporting the deployment of CE-IVD and FDA-cleared AI platforms for cancer diagnostics across a portfolio of enterprise partnerships. She is also the holder of a software patent focused on interoperability between emerging and legacy software applications.She is a published author across both academic and commercial domains.

Beyond her operating experience, Dr. Mina Lakshman is deeply engaged in Canada’s innovation and venture ecosystem. She holds a board position at Tamil Venture Zone where she leads international impact of woman-led ventures in a Global Affairs Canada funded program in partnership with DMZ Ventures. She is an Expert-in-Residence at Brampton Venture Zone, where she advises AI in Health launch Cohort and holds a seat for capital deployment to support early-stage companies. She has served on advisory boards for healthcare imaging and AI startups and contributes as an investment readiness reviewer for leading North American venture capital and angel investor networks

Her governance and leadership contributions extend to serving as an Industry Board Member of an Molecular Imaging Society and as governance lead on multi-site NIH-funded initiatives developing regulatory-grade clinical AI solutions and program management of Ontario Cancer Institute’s Diagnostic Development

At H2i, she brings a unique perspective grounded in scientific rigor, commercial execution, venture development, and digital transformation, helping innovators navigate the journey from breakthrough discovery to real-world impact.